Evidence map›Paper›PMID 36015043›Full record

ArticlePathogens (Basel, Switzerland)2022

WO

Ryosuke Matsuura, Ken Maeda, Kyoji Hagiwara, Yosuke Mori, Toru Kitamura, Yasunobu Matsumoto, Yoko Aida

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. TiOToxics · 2023
    Article
  5. Can photocatalysis help in the fight against COVID-19 pandemic?Current opinion in green and sustainable chemistry · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ryosuke MatsuuraLaboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Ken MaedaDepartment of Veterinary Science, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.ORCID 0000-0002-3488-5439
Kyoji HagiwaraAdvintage Co., Ltd., 1-1-1-705 Ebisuminami, Shibuya-ku, Tokyo 150-0022, Japan.
Yosuke MoriAdvintage Co., Ltd., 1-1-1-705 Ebisuminami, Shibuya-ku, Tokyo 150-0022, Japan.
Toru KitamuraCentre for Advanced Materials and Energy Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei.
Yasunobu MatsumotoLaboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
Yoko AidaLaboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.ORCID 0000-0001-7400-3587

Funding

Advintage Co., Ltd. Joint research fundOffice for Novel Coronavirus Disease Control, Cabinet Secretariat, Government of Japan (COVID-19 AI and Simulation Project) Cabinet Secretariat fund
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019, which has been a global pandemic. Since SARS-CoV-2 is transmitted through contaminated surfaces and aerosols, environmental disinfection is important to block the spread of the virus. Photocatalysts are attractive tools for virus inactivation and are widely used as air purifiers and coating materials. However, photocatalysts are inactive in the dark, and some of them need to be excited with light of a specific wavelength. Therefore, photocatalysts that can effectively inactivate SARS-CoV-2 in indoor environments are needed. Here, we show that a WO

Indexed as

copper based disinfectiondose-dependencyenvironmental disinfectionOmicron variant BA.2Pango lineage ASARS-CoV-2 inactivationtime-dependencyWO3 photocatalyst

Identifiers

PMID36015043
PMCPMC9415178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.